Aldevron
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Growth Equity VC | ||
N/A | Buyout | ||
$9.6b Valuation: $9.6b | Acquisition | ||
Total Funding | - |
Related Content
Recent News about Aldevron
EditAldevron is a leading provider of high-quality plasmid DNA, proteins, enzymes, and other biological materials essential for groundbreaking scientific research. The company serves a diverse range of clients, including academic institutions, biotechnology firms, and pharmaceutical companies, operating within the life sciences market. Aldevron's business model revolves around custom development and manufacturing services, offering both contract services and comprehensive solutions tailored to meet the specific needs of its clients. The company generates revenue through the sale of its biological products and services, ensuring expert support at every stage of development and production. Aldevron's advanced facilities are designed to support a continuous path from research to finished product, with capabilities that include ISO 13485 certified quality management systems, dedicated recombinant protein expression and purification suites, and multiple growth and purification scales. As part of Danaher Corporation, Aldevron combines best-in-class products and services with an ideal operating environment to foster vital new discoveries worldwide.
Keywords: plasmid DNA, proteins, enzymes, life sciences, biotechnology, pharmaceutical, custom development, manufacturing, research, Danaher.